Report Overview:
Narcolepsy is a chronic neurological disorder that results in extreme daytime sleepiness, often leading to sudden sleep attacks and affecting a person’s ability to stay awake.
Common symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy (a sudden loss of muscle strength), hypnagogic hallucinations (vivid, dream-like experiences), and sleep paralysis. The narcolepsy treatment market revolves around the provision of medical treatments and therapies to manage these symptoms and improve patients' quality of life.
Market Value:
The narcolepsy treatment market was valued at USD 2775.50 million in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 2.50% from 2024 to 2032, reaching USD 3381.68 million by 2032.
By Types:
• Sodium Oxybate
• Antidepressants
• Central Nervous System Stimulants
By Applications:
Primary Narcolepsy with Cataplexy
Primary Narcolepsy without Cataplexy
Narcolepsy Due to Medical Conditions
Unspecified Narcolepsy
Key players include:
• Teva Pharmaceutical
• Takeda
• Jazz Pharmaceuticals
• Arena Pharmaceuticals
• Graymark Healthcare
• Including or Excluding key companies relevant to your analysis.
